[go: up one dir, main page]

MX2020009947A - Amidas heterocíclicas útiles como moduladores de proteínas. - Google Patents

Amidas heterocíclicas útiles como moduladores de proteínas.

Info

Publication number
MX2020009947A
MX2020009947A MX2020009947A MX2020009947A MX2020009947A MX 2020009947 A MX2020009947 A MX 2020009947A MX 2020009947 A MX2020009947 A MX 2020009947A MX 2020009947 A MX2020009947 A MX 2020009947A MX 2020009947 A MX2020009947 A MX 2020009947A
Authority
MX
Mexico
Prior art keywords
sup
protein modulators
heterocyclic amides
amides useful
useful
Prior art date
Application number
MX2020009947A
Other languages
English (en)
Other versions
MX387354B (es
Inventor
Yue Li
Yiqian Lian
Adam Kenneth Charnley
Michael G Darcy
Jason W Dodson
Terry V Hughes
Neysa Nevins
Joshi M Ramanjulu
Xiaoyang Dong
Jianxing Kang
Lara Kathryn Leister
John F Mehlmann
Joseph J Romano
Gren Z Wang
Guosen Ye
Daohua Zhang
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2020009947A publication Critical patent/MX2020009947A/es
Publication of MX387354B publication Critical patent/MX387354B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se describen compuestos que tienen la fórmula: (ver Fórmula) en donde q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, y R17, son como se definen en la presente memoria, o un tautómero de los mismos, o una sal, en particular una sal farmacéuticamente aceptable de los mismos.
MX2020009947A 2016-04-07 2017-04-05 Amidas heterocíclicas útiles como moduladores de proteínas. MX387354B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662319358P 2016-04-07 2016-04-07
US201762461301P 2017-02-21 2017-02-21
US201762461975P 2017-02-22 2017-02-22
PCT/IB2017/051945 WO2017175147A1 (en) 2016-04-07 2017-04-05 Heterocyclic amides useful as protein modulators

Publications (2)

Publication Number Publication Date
MX2020009947A true MX2020009947A (es) 2021-10-26
MX387354B MX387354B (es) 2025-03-18

Family

ID=58503675

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020009948A MX387353B (es) 2016-04-07 2017-04-05 Amidas heterocíclicas útiles como moduladores de proteínas.
MX2020009947A MX387354B (es) 2016-04-07 2017-04-05 Amidas heterocíclicas útiles como moduladores de proteínas.
MX2018012333A MX379169B (es) 2016-04-07 2017-04-05 Amidas heterocíclicas útiles como moduladores de proteínas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020009948A MX387353B (es) 2016-04-07 2017-04-05 Amidas heterocíclicas útiles como moduladores de proteínas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018012333A MX379169B (es) 2016-04-07 2017-04-05 Amidas heterocíclicas útiles como moduladores de proteínas.

Country Status (33)

Country Link
US (4) US10981901B1 (es)
EP (2) EP3440076B1 (es)
JP (4) JP6746712B2 (es)
KR (2) KR102527784B1 (es)
CN (3) CN109608443B (es)
AU (4) AU2017247798C1 (es)
CA (1) CA3019630A1 (es)
CL (3) CL2018002850A1 (es)
CO (1) CO2018010727A2 (es)
CR (2) CR20200045A (es)
DK (1) DK3440076T3 (es)
DO (3) DOP2018000217A (es)
ES (1) ES2921855T3 (es)
HR (1) HRP20220936T1 (es)
HU (1) HUE058932T2 (es)
IL (4) IL295649B2 (es)
JO (1) JOP20170083B1 (es)
LT (1) LT3440076T (es)
MX (3) MX387353B (es)
MY (1) MY189100A (es)
NZ (1) NZ745957A (es)
PE (3) PE20181920A1 (es)
PH (3) PH12018502151B1 (es)
PL (1) PL3440076T3 (es)
PT (1) PT3440076T (es)
RS (1) RS63462B1 (es)
SG (3) SG10201900628RA (es)
SI (1) SI3440076T1 (es)
SM (1) SMT202200339T1 (es)
TW (3) TWI777014B (es)
UA (1) UA123407C2 (es)
UY (1) UY37195A (es)
WO (1) WO2017175147A1 (es)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202010609QA (en) 2015-08-13 2020-11-27 Merck Sharp & Dohme Cyclic di-nucleotide compounds as sting agonists
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3692996A1 (en) 2016-03-18 2020-08-12 Immune Sensor, LLC Cyclic di-nucleotide compounds and methods of use
IL295649B2 (en) * 2016-04-07 2025-12-01 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
MA46452B1 (fr) 2016-10-04 2021-10-29 Merck Sharp & Dohme Composés de benzo[b]thiophéne en tant qu'agonistes de sting
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ， インク． ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物
EP3609922A2 (en) 2017-04-13 2020-02-19 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
CA3071538A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Benzo[b]thiophene sting agonists for cancer treatment
JP7262451B2 (ja) * 2017-10-05 2023-04-21 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｓｔｉｎｇアゴニストの投与方法
EP3692033A1 (en) * 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
JP7291130B2 (ja) * 2017-10-05 2023-06-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
SG11202004113VA (en) 2017-11-10 2020-06-29 Takeda Pharmaceuticals Co Sting modulator compounds, and methods of making and using
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
US11685761B2 (en) 2017-12-20 2023-06-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CN110016025B (zh) * 2018-01-08 2021-08-06 成都先导药物开发股份有限公司 一种免疫调节剂
CN110016021B (zh) * 2018-01-08 2021-05-07 成都先导药物开发股份有限公司 一种免疫调节剂
RU2020129785A (ru) * 2018-02-16 2022-03-16 Юсб Байофарма Срл Фармацевтические производные 6,5-гетеробициклического кольца
EP3768266A4 (en) * 2018-03-20 2021-12-22 Merck Sharp & Dohme Corp. OXO-TETRAHYDRO-ISOCHINOLINE-CARBOXYLIC ACIDS AS STING INHIBITORS
IL309265A (en) 2018-03-23 2024-02-01 Codiak Biosciences Inc Extracellular vesicles containing agonist-STING
KR102755259B1 (ko) 2018-04-03 2025-01-15 머크 샤프 앤드 돔 엘엘씨 Sting 효능제로서의 벤조티오펜 및 관련 화합물
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
MA52754A (fr) * 2018-05-25 2021-04-14 Incyte Corp Composés hétérocycliques tricycliques en tant qu'activateurs de sting
CN112351778B (zh) * 2018-06-28 2023-04-04 江苏恒瑞医药股份有限公司 稠合三环杂环类化合物及其治疗用途
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
US11008344B2 (en) 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
CN112661772B (zh) 2018-08-24 2022-06-10 杭州阿诺生物医药科技有限公司 干扰素基因刺激蛋白化合物及其制备方法
EP3841112A1 (en) 2018-08-24 2021-06-30 Codiak BioSciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
US12364702B2 (en) 2018-08-29 2025-07-22 Adlai Nortye Biopharma Co., Ltd. Highly active sting protein agonist compound
IL315138A (en) 2018-09-06 2024-10-01 Daiichi Sankyo Co Ltd Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020115676A1 (en) 2018-12-06 2020-06-11 Glaxosmithkline Intellectual Property Development Limited Novel pharmaceutical formulation
CN113195473B (zh) * 2018-12-14 2022-11-22 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途
WO2020132566A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting pyrazole agonists and uses thereof
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
US12129267B2 (en) 2019-01-07 2024-10-29 Incyte Corporation Heteroaryl amide compounds as sting activators
CN111471056B (zh) * 2019-01-23 2021-07-02 成都先导药物开发股份有限公司 一种大环类免疫调节剂
AU2020214477B2 (en) * 2019-01-31 2022-10-27 Hitgen Inc. Immunomodulator
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
CA3129011C (en) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CA3129022C (en) 2019-03-07 2023-08-01 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
AU2020240135A1 (en) 2019-03-21 2021-10-14 Lonza Sales Ag Extracellular vesicles for vaccine delivery
AU2020241903A1 (en) 2019-03-21 2021-10-14 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
KR20210146370A (ko) 2019-03-28 2021-12-03 루핀 리미티드 Sting 효능제로서의 매크로사이클릭 화합물
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
WO2021000770A1 (zh) * 2019-07-02 2021-01-07 凯复制药有限公司 可增强免疫活性的杂环化合物、其制备方法及其在医药上的应用
EP3994158A1 (en) 2019-07-03 2022-05-11 Codiak BioSciences, Inc. Extracellular vesicles targeting t cells and uses thereof
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
GB201910305D0 (en) * 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
RS66126B1 (sr) 2019-07-22 2024-11-29 Lupin Ltd Makrociklična jedinjenja kao agonisti uboda i njihove metode i upotreba
CN112279835B (zh) * 2019-07-24 2022-07-22 中国医学科学院药物研究所 芳环或芳杂环并咪唑类化合物，其制备方法及制药用途
CN114206898B (zh) 2019-07-25 2024-06-25 百济神州有限公司 作为sting激动剂的环状二核苷酸
US20220267364A1 (en) * 2019-07-25 2022-08-25 Shanghai Jemincare Pharmaceuticals Co., Ltd. Heterocyclic amide compound, preparation method therefor and use thereof
JP2022543086A (ja) * 2019-08-02 2022-10-07 メルサナ セラピューティクス インコーポレイテッド がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
CN112521394A (zh) * 2019-09-19 2021-03-19 中国药科大学 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
CN112521371B (zh) * 2019-09-19 2022-11-25 中国药科大学 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
EP4034247A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
WO2021062290A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
CA3152488A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Combination therapy using extracellular vesicles
JP2022549328A (ja) 2019-09-25 2022-11-24 コディアック バイオサイエンシーズ， インコーポレイテッド 細胞外小胞組成物
TW202115084A (zh) * 2019-10-10 2021-04-16 英屬開曼群島商百濟神州有限公司 作為sting調節劑之雜環化合物
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
CN112778336B (zh) * 2019-11-02 2023-05-05 上海凌达生物医药有限公司 一类含氮稠环类sting调节剂类化合物、制备方法和用途
CN112940004B (zh) * 2019-12-11 2022-07-12 中国科学院上海药物研究所 一种杂环化合物及其用途
JP7662644B2 (ja) * 2019-12-18 2025-04-15 シーティーエックスティー・ピーティーワイ・リミテッド 化合物
CN113087668B (zh) * 2019-12-23 2022-11-04 中国科学院上海药物研究所 一类苯并咪唑二聚体、其制备方法及用途
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
CN115209921B (zh) 2020-03-06 2025-06-24 第一三共株式会社 包含环状二核苷酸衍生物的抗体药物偶联物
US20230114434A1 (en) 2020-03-13 2023-04-13 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
EP4121450A2 (en) 2020-03-20 2023-01-25 Codiak BioSciences, Inc. Extracellular vesicles for therapy
JP2023520513A (ja) 2020-04-02 2023-05-17 メルサナ セラピューティクス インコーポレイテッド Ｓｔｉｎｇアゴニストを含む抗体薬物コンジュゲート
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
AU2021338438A1 (en) * 2020-09-02 2023-03-23 The Scripps Research Institute Agonists of stimulator of interferon genes sting
CA3191395A1 (en) 2020-09-02 2022-03-10 Daiichi Sankyo Company, Limited Novel endo-.beta.-n-acetylglucosaminidase
EP4216993A2 (en) 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
US20220168330A1 (en) 2020-11-09 2022-06-02 Takeda Pharmaceutical Company Limited Antibody drug conjugates
MX2023008327A (es) 2021-01-15 2023-08-22 Seagen Inc Anticuerpos inmunomoduladores de anticuerpo-farmaco.
CN112920172B (zh) * 2021-02-01 2022-03-22 厦门大学 一种干扰素刺激蛋白靶向化合物、其放射性标记物、及它们的制备方法与应用
KR102881036B1 (ko) * 2021-02-17 2025-11-05 한국화학연구원 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물
WO2022177307A1 (ko) * 2021-02-17 2022-08-25 한국화학연구원 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물
WO2022223619A1 (en) 2021-04-20 2022-10-27 Institut Curie Compositions and methods for use in immunotherapy
US20240285755A1 (en) 2021-05-24 2024-08-29 Glaxosmithkline Biologicals Sa Adjuvants
WO2022246597A1 (en) * 2021-05-24 2022-12-01 Forever Millets Limited Imidazopyridine derivatives as sting agonists
WO2022272039A1 (en) * 2021-06-25 2022-12-29 Bolt Biotherapeutics, Inc. Bis-benzimidazole sting agonist immunoconjugates, and uses thereof
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023025256A1 (zh) * 2021-08-26 2023-03-02 成都先导药物开发股份有限公司 一种适合作为抗体偶联药物效应分子的sting激动剂
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
AU2023207026A1 (en) * 2022-01-11 2024-06-20 Bisichem Co., Ltd. Fused heteroaryl hydroxamates as sting agonists
EP4472739A1 (en) * 2022-02-02 2024-12-11 F. Hoffmann-La Roche AG Imidazole macrocycles for the treatment of autoimmune disease
CN118742328A (zh) 2022-02-22 2024-10-01 阿拉里斯生物技术股份公司 包含两个或更多个有效载荷的肽接头
EP4488378A1 (en) 2022-03-02 2025-01-08 Daiichi Sankyo Company, Limited Method for producing fc-containing molecule
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
PE20250259A1 (es) 2022-07-05 2025-01-29 Pfizer Compuestos de pirido[4,3-d] pirimidina
KR20250054799A (ko) 2022-08-29 2025-04-23 다이이찌 산쿄 가부시키가이샤 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
CN120712250A (zh) * 2022-10-03 2025-09-26 托马斯杰斐逊大学 基于吡咯烷和咪唑烷的DNA聚合酶θ抑制剂及其用途
WO2024074977A1 (en) 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
CN120379671A (zh) 2022-10-18 2025-07-25 辉瑞公司 用于治疗癌症的化合物
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
WO2024137619A1 (en) 2022-12-20 2024-06-27 Bolt Biotherapeutics, Inc. Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
WO2024180103A1 (en) 2023-02-27 2024-09-06 BioNTech SE Sting agonists containing benzylic alcohol and benzylic amine functional groups
EP4673439A1 (en) 2023-02-27 2026-01-07 BioNTech SE Sting agonists containing hydrazide, hydrazine, and hydroxamic acid functional groups
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
CR20250413A (es) 2023-04-05 2025-11-06 Pfizer Compuestos de pirido[4,3–d]pirimidina
WO2024213979A1 (en) 2023-04-10 2024-10-17 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
AR133199A1 (es) * 2023-07-10 2025-09-03 Hoffmann La Roche Macrociclos bicíclicos para el tratamiento de enfermedades autoinmunitarias
WO2025029832A2 (en) * 2023-07-31 2025-02-06 Sutro Biopharma, Inc. Sting agonist compounds and conjugates
KR20250040871A (ko) * 2023-09-15 2025-03-25 삼진제약주식회사 Sting(인터페론 유전자 자극인자) 활성화제로서의 헤테로 고리 유도체 및 이를 포함하는 약학적 조성물
EP4534147A1 (en) 2023-10-05 2025-04-09 Sulis Therapeutics ApS Sting antagonist compounds
WO2025094035A1 (en) 2023-11-01 2025-05-08 Pfizer Inc. Toll-like receptor agonists and conjugates thereof
EP4663204A1 (en) 2024-06-13 2025-12-17 Sulis Therapeutics ApS Compounds useful for the modulation of the activity of sting
EP4663632A1 (en) * 2024-06-13 2025-12-17 Sulis Therapeutics ApS Compounds useful for the modulation of the activity of sting
WO2026027944A1 (en) 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
CA2310896A1 (en) 1999-07-02 2001-01-02 Japan Tobacco Inc. Hcv polymerase suitable for crystal structure analysis and method for using the enzyme
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2589418A1 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
ID30204A (id) 1999-12-27 2001-11-15 Japan Tobacco Inc Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat
AU2001269695B2 (en) 2000-05-19 2007-02-15 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-based compounds
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AU2001281001B2 (en) 2000-08-04 2005-11-03 Corixa Corporation New immunoeffector compounds
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
EP1539188B1 (en) 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US7285552B2 (en) 2001-03-19 2007-10-23 Ono Pharmaceuticals Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
WO2003085375A2 (en) 2002-04-04 2003-10-16 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
EP2243493A1 (en) 2002-07-03 2010-10-27 Ono Pharmaceutical Co., Ltd. Immunopotentiative composition
TW200418848A (en) 2002-10-24 2004-10-01 Glaxo Group Ltd Compounds
CN1731993A (zh) 2002-11-01 2006-02-08 维洛药品公司 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法
WO2004054581A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
US7271172B2 (en) 2002-12-13 2007-09-18 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as CCR5 antagonists
DE60318891T2 (de) 2002-12-13 2009-01-22 Smithkline Beecham Corp. Cyclopropylverbindungen als ccr5 antagonisten
US7531661B2 (en) 2002-12-13 2009-05-12 Smithkline Beecham Corporation Indane compounds as CCR5 antagonists
CA2509711A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
EP1569931B1 (en) 2002-12-13 2008-10-08 Smithkline Beecham Corporation Heterocyclic compounds as ccr5 antagonists
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
TW200517381A (en) 2003-08-01 2005-06-01 Genelabs Tech Inc Bicyclic heteroaryl derivatives
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
WO2005070420A1 (en) 2004-01-14 2005-08-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1h-benzimidazol-2-yl-benzamide derivatives and related compounds as itk inhibitors (interleukin-2-inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
EA200901463A1 (ru) 2004-02-20 2010-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
EP1729781B1 (en) 2004-03-15 2012-10-24 Karaolis, David K. R. A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
CA2564175A1 (en) 2004-04-28 2005-11-10 Arrow Therapeutics Limited Chemical compounds
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
AU2005273619B2 (en) 2004-08-18 2009-05-28 Pfizer Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
US20070060589A1 (en) * 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
CA2607089A1 (en) 2005-05-04 2006-11-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
BRPI0608910A2 (pt) 2005-05-09 2010-02-17 Achillion Pharmaceuticals Inc uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
MX2007013978A (es) 2005-05-09 2008-02-22 Ono Pharmaceutical Co Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
RS54876B1 (sr) 2005-05-10 2016-10-31 Incyte Holdings Corp Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20100017514A (ko) 2007-05-07 2010-02-16 메디뮨 엘엘씨 항 ｉｃｏｓ 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
KR101562580B1 (ko) 2007-06-18 2015-10-22 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
DK2242771T3 (da) 2007-12-14 2013-08-26 Pfizer Bindingsmolekyler til den humane ox40-receptor
SG187502A1 (en) 2008-02-01 2013-02-28 Takeda Pharmaceutical Oxim derivatives as hsp90 inhibitors
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
US8148363B2 (en) * 2008-05-19 2012-04-03 Schering Corporation Heterocyclic compounds as factor IXA inhibitors
WO2013166000A1 (en) 2012-04-30 2013-11-07 Barber Glen N Modulating immune responses
WO2010027827A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
CN102264762B (zh) 2008-09-26 2018-03-27 达纳-法伯癌症研究公司 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
BRPI0917592B1 (pt) 2008-12-09 2021-08-17 Genentech, Inc Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
AU2010229795A1 (en) 2009-03-27 2011-10-13 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis C
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) * 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
US8598156B2 (en) * 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
EA025281B9 (ru) * 2010-05-17 2017-08-31 Инкозен Терапьютикс Пвт. Лтд. СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
CN101898945B (zh) 2010-07-27 2013-05-08 大连理工大学 盐析萃取发酵液中丙酮和丁醇的方法
WO2013028231A1 (en) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
AP2013006771A0 (en) 2010-08-23 2013-03-31 Boards Of Regents The University Of Texas System Anti-OX40 antibodies and methods of using the same
US20140364617A1 (en) * 2010-12-15 2014-12-11 Abbvie Inc. Anti-viral compounds
SG193428A1 (en) 2011-03-31 2013-10-30 Inst Nat Sante Rech Med Antibodies directed against icos and uses thereof
SG10201606284UA (en) 2011-08-01 2016-09-29 Genentech Inc Methods Of Treating Cancer Using Pd-1 Axis Binding Antagonists And Mek Inhibitors
CA3213528A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
SG10201610251PA (en) 2012-06-08 2017-01-27 Aduro Biotech Compositions and methods for cancer immunotherapy
WO2014001464A1 (en) * 2012-06-27 2014-01-03 4Sc Discovery Gmbh Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
ES2684552T3 (es) 2012-09-03 2018-10-03 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
PT2931738T (pt) 2012-12-13 2019-04-10 Aduro Biotech Inc Composições compreendendo nucleótidos cíclicos de purina com estereoquímica definida e métodos para a sua preparação e utilização
PT2996473T (pt) 2013-05-18 2019-11-18 Univ California Composições e métodos para a ativação da sinalização dependente do ''estimulador de genes de interferão''
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
US10227638B2 (en) 2014-06-02 2019-03-12 Base4 Innovation Ltd. Nucleotide polymorphism detection method
CR20160564A (es) * 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
RU2715038C2 (ru) 2014-07-11 2020-02-21 Дженентек, Инк. Антитела анти-pd-l1 и способы их диагностического применения
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
CN114907481A (zh) 2015-03-23 2022-08-16 震动疗法股份有限公司 Icos的抗体
SG10202010609QA (en) 2015-08-13 2020-11-27 Merck Sharp & Dohme Cyclic di-nucleotide compounds as sting agonists
RU2020113165A (ru) 2015-12-03 2020-06-09 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Циклические пуриновые динуклеотиды в качестве модуляторов sting
IL295649B2 (en) 2016-04-07 2025-12-01 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators

Also Published As

Publication number Publication date
BR122018070836A8 (pt) 2022-07-19
CR20200045A (es) 2020-03-11
IL285702A (en) 2021-09-30
JP6861307B2 (ja) 2021-04-21
TWI777014B (zh) 2022-09-11
HRP20220936T1 (hr) 2022-10-28
IL261657B (en) 2021-09-30
MY189100A (en) 2022-01-25
DOP2020000018A (es) 2020-03-15
IL261482B (en) 2021-09-30
TWI868471B (zh) 2025-01-01
CN109071514A (zh) 2018-12-21
LT3440076T (lt) 2022-09-26
JP2020100646A (ja) 2020-07-02
IL261482A (en) 2018-10-31
AU2020200692A1 (en) 2020-02-20
ES2921855T3 (es) 2022-09-01
DOP2020000019A (es) 2020-03-15
CL2018003290A1 (es) 2019-02-01
AU2018229498C1 (en) 2020-09-03
CL2018003291A1 (es) 2019-02-01
CN109071514B (zh) 2021-07-06
MX2018012333A (es) 2019-03-07
UA123407C2 (uk) 2021-03-31
NZ745957A (en) 2020-07-31
MX379169B (es) 2025-03-10
PH12018502202A1 (en) 2020-06-22
KR20180132806A (ko) 2018-12-12
PE20181920A1 (es) 2018-12-11
JP2022166060A (ja) 2022-11-01
US11365190B2 (en) 2022-06-21
AU2017247798A1 (en) 2018-09-27
AU2018229497A1 (en) 2018-10-04
DOP2018000217A (es) 2018-10-31
PH12018502151A1 (en) 2019-07-08
AU2018229498B2 (en) 2019-06-27
UY37195A (es) 2017-10-31
US11970480B2 (en) 2024-04-30
JOP20170083B1 (ar) 2022-03-14
AU2020200692C1 (en) 2021-03-04
AU2018229497B2 (en) 2019-06-27
CO2018010727A2 (es) 2018-10-22
CR20200044A (es) 2020-03-11
KR20180124149A (ko) 2018-11-20
US20210139473A1 (en) 2021-05-13
MX387353B (es) 2025-03-18
PH12018502179A1 (en) 2020-06-15
AU2020200692B2 (en) 2020-08-27
CN113549110A (zh) 2021-10-26
AU2017247798B2 (en) 2019-10-31
BR122018070836A2 (pt) 2019-09-10
PE20181919A1 (es) 2018-12-11
SMT202200339T1 (it) 2022-09-14
TW201920161A (zh) 2019-06-01
PT3440076T (pt) 2022-07-29
KR102527786B1 (ko) 2023-04-28
JP7119158B2 (ja) 2022-08-16
JP2019510796A (ja) 2019-04-18
CL2018002850A1 (es) 2018-12-14
SG11201808621TA (en) 2018-10-30
BR122018070838A8 (pt) 2022-07-19
WO2017175147A1 (en) 2017-10-12
TW201738235A (zh) 2017-11-01
CN113549110B (zh) 2024-08-16
JP2021105013A (ja) 2021-07-26
HUE058932T2 (hu) 2022-09-28
AU2017247798C1 (en) 2020-08-27
IL261657A (en) 2018-10-31
JP7466596B2 (ja) 2024-04-12
SG10201900628RA (en) 2019-02-27
IL295649A (en) 2022-10-01
CN109608443B (zh) 2021-09-07
NZ750114A (en) 2025-05-30
BR112018070655A2 (pt) 2019-02-05
TW202246285A (zh) 2022-12-01
CA3019630A1 (en) 2017-10-12
US10189820B2 (en) 2019-01-29
JP6746712B2 (ja) 2020-08-26
RS63462B1 (sr) 2022-08-31
IL295649B1 (en) 2025-08-01
EP3440076B1 (en) 2022-06-01
US20180105514A1 (en) 2018-04-19
PE20181884A1 (es) 2018-12-07
TWI776806B (zh) 2022-09-11
MX2020009948A (es) 2021-10-26
AU2018229498A1 (en) 2018-10-04
SI3440076T1 (sl) 2022-09-30
EP3440076A1 (en) 2019-02-13
CN109608443A (zh) 2019-04-12
SG10201900629VA (en) 2019-02-27
AU2018229497C1 (en) 2020-09-03
US20230071675A1 (en) 2023-03-09
PL3440076T3 (pl) 2022-09-05
PH12018502151B1 (en) 2022-01-12
EP4032885A1 (en) 2022-07-27
KR102527784B1 (ko) 2023-04-28
DK3440076T3 (da) 2022-07-11
US10981901B1 (en) 2021-04-20
MX387354B (es) 2025-03-18
IL295649B2 (en) 2025-12-01
BR122018070838A2 (pt) 2019-09-10
IL285702B (en) 2022-09-01

Similar Documents

Publication Publication Date Title
MX2020009947A (es) Amidas heterocíclicas útiles como moduladores de proteínas.
PH12018502136A1 (en) Heterocyclic amides useful as protein modulators
CY1124187T1 (el) Ετεροκυκλικα αμιδια ως αναστολεις κινασης
LT3577110T (lt) 8-oksetan-3-il-3,8-diazabiciklo[3.2.1]oktan-3-ilo pakeistieji junginiai, kaip živ inhibitoriai
AR123656A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina
EP3632907C0 (en) N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
LT3805220T (lt) Policikliniai karbamoilpiridono dariniai, skirti živ gydymui
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
MA49127A (fr) Dérivés d'indole n-substitués
MX383577B (es) Derivados sustituidos de guanidina.
MX2019011774A (es) N-(-1,3,4-oxadiazol-2-il)arilcarboxamidas sustituidas y su uso como herbicidas.
HUE045226T2 (hu) Herbicid hatású N-(1,3,4-oxadiazol-2-il)arilkarboxamid-származékok
TR201901977T4 (tr) Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri.
EP3643311C0 (en) 4-OXO-ALKYLATED TETRAMIC ACID COMPOUND, PREPARATION METHOD AND USE THEREOF
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
MA55010A (fr) Système d'électrodes
WO2018211324A8 (en) Prodrugs for the treatment of disease
EA201892261A1 (ru) Гетероциклические амиды, пригодные в качестве модуляторов белков
EA201990506A1 (ru) Фармацевтическая композиция
EA201991141A1 (ru) Усилители bmp
EA201692485A1 (ru) Новая полиморфная форма n-[2-(6-фтор-1h-индол-3-ил)этил]-3-(2,2,3,3-тетрафторпропокси)бензиламина гидрохлорида для лечения болезни альцгеймера
EP3925957A4 (en) 1,3-DIOXOLANE DERIVATIVE
UA106614U (uk) N-(фенілгідразидоацетил)-n'-cукцинамідоантраніламід, який виявляє протисудомну активність
SE1500382A1 (sv) Passive Wireless Repeater